Surgical injury can be a life-threatening complication, not only due to the injury itself, but also due to immune responses to the injury and subsequent development of infections, which readily result in sepsis. Sepsis remains the leading cause of death in most intensive care units. Unfavorable outcomes of several high-profile trials in the treatment of sepsis have led researchers to state that sepsis studies need a new direction. The immune response that occurs during sepsis is characterized by a cytokine-mediated hyper-inflammatory phase, which most patients survive, and a subsequent immunosuppressive phase. Therefore, therapies that improve host Sepsis is a common and frequently fatal clinical condition occurring in critically ill patients. Septic patients frequently present with fever, shock, and respiratory failure as a result of an uncontrolled proinflammatory response that has been termed systemic inflammatory response syndrome (SIRS). 1 Definitions of sepsis were last revised in 1992. These definitions were focused on the SIRS of the host to infection. However, the validity of SIRS as an indicator of sepsis pathobiology has remained controversial. Sepsis is now recognized to involve the early activation of both pro-and anti-inflammatory responses. The current use of ≥2 SIRS criteria to identify sepsis was unanimously considered by the task force to be unhelpful. The SIRS criteria do not necessarily indicate a dysregulated life-threatening response. Thus, the public is in need of an understandable
definition of sepsis. Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. Organ dysfunction was identified as an acute change in total Sequential Organ Failure Assessment score 2 (SOFA) of ≥2 as a consequence of the infection (Table 1) .
| ME CH ANISM OF SEPSIS -INDUCED IMMUNOSUPPRESSION
This initial immune recognition response is mediated by pathogenassociated molecular patterns and damage-associated molecular patterns originating from bacterial or fungal organisms that blind pattern recognition receptors expressed on innate immune cells. 3 The activa- endothelial injury with capillary leak, and activation of the coagulation system. 4 Until recently, most research on sepsis was focused on blocking the initial hyper-inflammatory response. Initially, the proinflammatory response was believed to be the major cause of mortality in patients with sepsis and was frequently targeted for therapeutic intervention. 5 However, efforts to improve outcomes by targeting proinflammatory cytokines and mediators, such as TNF and IL-1β antagonists, endotoxin antagonists, Toll-like receptor (TLR) blockers, and platelet activating factor inhibitors, have been unsuccessful. 6 This profound proinflammatory state, which occurs during the early onset of sepsis, is rapidly counterbalanced by an antiinflammatory response, which may adversely affect immune functions. 7 This was initially referred to as compensatory anti-inflammatory response syndrome. 8 The vast majority of patients with sepsis survive the initial insult. Sepsis-induced immunosuppression is increasingly recognized as the overriding immune dysfunction in these vulnerable patients 7 ( Figure 1 
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Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. Organ dysfunction can be identified as an acute change in total SOFA score of ≧2 points consequent to infection. MAP, mean arterial pressure; SOFA, Sequential Organ Failure Assessment.
| Apoptosis and immunosuppression
Apoptosis is an irreversible reaction in which the immune system maintains homeostasis by eliminating activated cells. 12 Central to apoptosis are caspases, which are cysteine proteases that degrade cellular proteins and nuclear factor-kappa B (NF-κB), a transcription factor that activates the transcription of both proapoptotic and prosurvival genes. Whereas hyper-inflammatory responses of sepsis require NF-κB for the production of proinflammatory cytokines and the activation by caspase cleavage, both NF-κB and caspases concurrently induce the apoptosis of immune cells. 3 Consistent with this, a concurrent apoptotic response has been shown to be present in sepsis in association with the proinflammatory response. 13 Although the deletion of adaptive immune cells is recognized as an important part of the pathology of sepsis, the mechanisms responsible for this are not fully understood. 14 
| Monocytes and macrophages
We have already reported that patients with sepsis have monocytes with a decreased capacity to release proinflammatory cytokines in response to endotoxin. 18 This finding is consistent with the phe- by Treg cells and Th2-type cells and suppresses the Th1 response, further potentiating an anti-inflammatory environment. 23 We have reported that blocking IL-10 can reverse sepsis-induced immunosuppression and improve survival in a mouse model of sepsis. 24 Low levels of monocyte human leukocyte antigen (HLA)-DR expression function as a surrogate marker of monocyte unresponsiveness. 25 We previously reported that expression of the human leukocyte antigen HLA-DR by peripheral blood monocytes was decreased in septic patients, particularly in patients with septic shock or severe sepsis. 26 Several studies showed an association of reduced monocyte HLA-DR expression with impaired monocyte function.
These data show that monocyte unresponsiveness and immunosuppression independently contribute to the increased risk of adverse events in sepsis.
| Natural killer cells
Natural killer cells are the principle producers of IFN-γ during bacterial sepsis. 27 These cells produce a large amount of IFN-γ when stim- 
| T cells
In sepsis, T cells become hypo-responsive in terms of proliferation and turn toward a type 2 profile with an increased production of IL-4 and IL-10, and suppression of IL-12 and IFN-γ. We previously reported that serum IFN-γ levels and IFN-γ production by PBMC were significantly decreased in patients with sepsis compared with healthy volunteers. 28, 30 In the late 1990s, Sakaguchi et al 31 showed for the first time cell survival, whereas IL-7 is thought to be a cytokine that is targeted more toward T cells. IL-7 is a multifunctional cytokine of the immune system that affects both T cells and B cells and induces the proliferation of naïve and memory T cells. 44 Venet et al 45 showed
that IL-7 treatment of isolated lymphocytes from septic patients restored T-cell proliferation and IFN-γ secretion.
A recent study provided insight into the molecular mechanisms that underlie immune depression following sustained inflammation.
This study showed a crucial monocyte-macrophage protein known as PD-1, which is found in patients infected with the human immunodeficiency virus (HIV). PD-1, which is a negative costimulatory mole- present and may be dysregulated in human sepsis. 11, 48 In oncology,
anti-PD-1 and anti-PD-L antibody therapy have been used successfully to treat various tumors. 49 These data indicate that blocking the PD-1/PD-L1 axis is a promising target for restoring immune function in human sepsis.
| Polymyxin B direct hemoperfusion therapy for septic immunoparalysis
Polymyxin B (PMX) has long been known to neutralize the various biological activities of endotoxins. 50 In 1990, after the biocompatibility of F I G U R E 3 Immunostimulation therapies for sepsis. Targets of potential immunotherapeutic approaches include agents that block apoptosis, block negative costimulatory molecules, decrease the level of anti-inflammatory cytokines, increase human leukocyte antigen (HLA)-DR expression, and reactivate "exhausted" or anergic T cells. G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; NK, natural killer; PAMP, pathogen-associated molecular patterns; PD-1, programmed cell death-1; PD-L1, programmed cell death 1 ligand 1; PMX-DHP, polymyxin B direct hemoperfusion; TCR, T cell receptor; TGF, transforming growth factor; TLR, Toll-like receptor sterilized PMX-F (polymyxin B covalently immobilized on fibers) was demonstrated, the Critical Network Group in Japan obtained permission from the Japanese Ministry of Health and Welfare to clinically test hemoperfusion with PMX-F, and subsequently reported that it was safe and effective for patients with septic shock. 51, 52 The main objective of therapeutic apheresis is the removal of toxic substances, although the method can also be applied for immunomodulation. It was reported that the absorption of anandamide by polymyxin B might abolish the diverse negative effects of anandamide, such as hypotension, immunosuppression, and cytotoxicity, 53 and that the reduction of serum cytokine levels 54 or monocyte mRNA expression, 55 and the proapoptotic activity of plasma 56 from septic patients might contribute to the efficacy of hemoperfusion with PMX-F. We previously reported that the expression of HLA-DR surface antigen on monocytes is decreased in patients with septic shock, and that PMX-F therapy is effective for increasing its expression. 26 However, the molecular mechanism underlying these effects, and the potential of this treat- 
| FUTURE ASPECTS
Immunotherapy is expected to be used in individual patients on the basis of specific laboratory or clinical findings. For example, a recent trial of GM-CSF to treat sepsis tested the effect only on patients in whom monocyte HLA-DR expression was significantly suppressed.
Flow-cytometry data regarding the expression levels of negative costimulatory molecules, such as PD-1 and PD-L1, on leukocytes may be useful as a guide for deciding on immunotherapies.
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